publication venue for
- Points to consider: EULAR-UEMS standards for the training of European rheumatologists. 1107-1113. 2023
- Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism. 1594-1605. 2023
- The 2023 ACR-EULAR classification criteria for CPPD. 1248-1257. 2023
- 2 Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors 2022
- Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland. . 1-2. 2022
- Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.. 0-6. 2021
- 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training 2020
- Case series of acute arthritis during COVID-19 admission. 2020
- Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland 2020
- Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors 2020
- Influence of Covid19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries 2020
- Response to: 'Comparative analysis of synovial inflammation after SARS-CoV-2 infection' by Alivernini et al 2020
- Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. . 355-364. 2019
- Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.. 1592-1600. 2019
- Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. 1-10. 2018
- 2016 updated EULAR evidence-based recommendations for the management of gout. 29-42. 2017
- Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. 1263-1268. 2017
- GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes.. 869-877. 2017
- Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al. 2017
- SUA levels should not be maintained <3 mg/dL for several years. Response to 'EULAR gout treatment guidelines by Richette et al: uric acid and neurocognition by Singh et al' 2017
- EULAR evidence-based recommendations for the management of gout. 1-14. 2016
- Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al 2016
- A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk. 1875-1881. 2015
- Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout?. 1522-1528. 2014
- Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation.. 155-156. 2013
- Gout treatment: should we aim for rapid crystal. 635-637. 2013
- Gout treatment: should we aim for rapid crystal dissolution?. 635-637. 2013
- Gout: wht is this curable disease so seldom cured?. 1765-1770. 2012
- First metatarsophalangeal joint aspiration using a 29-Gauge needle. . 273-275. 2008
- The time required for disappearance of urate crystals from synovial fluid after successful hypouricemic treatment relates to the duration of gout. . 1056-1058. 2007
- Why should be gout so poorly treated? . 1269-1270. 2007
- "Crystal Clear" Sonographic Assesment of Gout and Calcium Pyrophosphate Deposition Disease. 2006
- EULAR evidence based recommendations for gout - Part I Diagnosis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). 1312-1324. 2006
- EULAR Evidence based recommendations for gout - part ii management: report of a task force or the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) . 1301-1311. 2006
- Gout, diuretics and the kidney.. 981-982. 2006
- Analysis for crystals in synovial fluid: training of the analysts results in high consistency. 612-615. 2005
- Analysis for crystals in synovial fluid: training of the analysts results in high consistency. 612-615. 2005
- Analysis for crystals in synovial fluid: training of the analysts results in high consistency. . 612-615. 2005
- Intracellular and extracellular CPPD crystals are a regular feature in synovial fluid from uninflamed joints of patients with CPPD related arthropathy. 1769-1772. 2005
- Most calcium pyrophosphate crystals appear as non-birefringent . 582-584. 1999